Rapamycin is a naturally occurring chemical first discovered in the soil on Easter Island (Rapa Nui) in the early 1970s. Rapamycin and its rapalogues are indicated for use in advanced stage cancer and anti-organ rejection therapies. Though rapamycin has demonstrated efficacy in multiple indications from cognition to cancer prevention, its low bio-availability, significant toxicity, and large interpatient pharmacokinetic variation (up to 8x) have limited its market potential.
eRapa™ was developed to improve rapamycin's pharmacokinetics. It is a a proprietary, patented, micro-encapsulated formulation of rapamycin that protects the active ingredient from rapid, low pH degradation in the stomach. The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer (Eudragit® L 100 / S 100).
eRapa™ has composition of matter and manufacturing patent protection through 2035.
Benefits of eRapa™ over rapamycin and current rapalogues include:
eRapa™ modulates the mTOR pathway, which controls cell growth, proliferation, nutrient transport, autophagy, and survival. Chronic, intermittent, low dose eRapa™: